Reported 1 day ago
H.C. Wainwright has upgraded CRISPR Therapeutics (NASDAQ:CRSP) with a new price target of $80, up from $65, citing a remarkable 41% year-to-date stock gain and a significant 114% increase in CASGEVy sales, reaching $30 million in Q2. This growth was propelled by infusions in 16 patients, double that of the previous quarter, and reflects the company's ongoing expansion in gene-editing treatments for serious diseases.
Source: YAHOO